Remit: To appraise the clinical and cost effectiveness of nivolumab with ipilumumab and standard chemotherapy (platinum-based combination chemotherapy) within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1566

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors Bristol-Myers Squibb (nivolumab, ipilimumab)
Others Department of Health and Social Care
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer Nursing UK
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Celgene (paclitaxel)
  Merck Sharpe and Dohme (pembrolizumab)
  Roche (atezolizumab, bevacizumab)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
12 May 2021 Committee meeting: 2
08 April 2021 - 26 April 2021 Appraisal consultation
11 March 2021 Committee meeting
07 July 2020 Invitation to participate
06 April 2020 - 07 May 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 April 2019 In progress. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance